Cyclophosphamide, Docetaxel, and non-pegylated liposomal doxorubicin combination

## Drug Information\n\nThis is a combination chemotherapy regimen used primarily in breast cancer treatment. The regimen consists of three distinct anticancer agents that work through different mechanisms to target cancer cells.\n\nThe search results primarily discuss studies involving pegylated liposomal doxorubicin (PLD) in combination with cyclophosphamide and/or docetaxel, rather than specifically non-pegylated liposomal doxorubicin. However, there is mention of non-pegylated liposomal doxorubicin being used in combination with either cyclophosphamide or docetaxel[4][5].\n\n### Components and Mechanism\n\nThis combination includes:\n\n1. **Cyclophosphamide** - An alkylating agent that works by cross-linking DNA strands, preventing cell division\n2. **Docetaxel** - A taxane that inhibits microtubule disassembly, preventing cell division\n3. **Non-pegylated liposomal doxorubicin** - An anthracycline encapsulated in liposomes that intercalates with DNA and inhibits topoisomerase II\n\nThe liposomal formulation of doxorubicin is designed to reduce cardiotoxicity while maintaining efficacy compared to conventional doxorubicin[1][2].\n\n### Clinical Application\n\nThis combination has been studied as neoadjuvant chemotherapy (NAC) for locally advanced breast cancer. Similar regimens using pegylated liposomal doxorubicin have shown:\n\n- Pathological complete response (pCR) rates of 15.4-18.75% overall[1][2]\n- Higher pCR rates (43.75%) in triple-negative breast cancer patients[1]\n- Overall response rates around 89%[2]\n- Reduced cardiotoxicity compared to conventional anthracycline regimens[1][2]\n\nThe treatment is typically administered in cycles, with each drug given at specific dosages on day 1 of a 21-day schedule. For example, one protocol used PLD 30-35 mg/m² and docetaxel 75-80 mg/m² on day 1 of each 21-day cycle for six cycles[2].\n\n### Safety Profile\n\nThe liposomal formulation of doxorubicin appears to have a more favorable cardiac safety profile compared to conventional doxorubicin, with studies showing no significant decrease in left ventricular ejection fraction and no symptomatic cardiac events[1][2]. This makes it potentially suitable for patients with heart abnormalities who require anthracycline-based chemotherapy[1].\n\nCommon side effects of this combination likely include bone marrow suppression, alopecia, gastrointestinal reactions, and other typical chemotherapy-related toxicities, though with potentially reduced cardiotoxicity compared to standard anthracycline regimens[1].